Monday, September 5, 2016 12:27 AM
LAKE FOREST, Calif.—ReVision Optics
announced the U.S. commercial launch of its Raindrop Near Vision Inlay. The launch plan calls for the company’s direct field force to focus on sites that participated in the U.S. IDE clinical trial, followed by a more broad-based expansion.
Wednesday, August 24, 2016 12:18 AM
DUBLIN, Ireland—Presbia PLC
(NASDAQ: LENS) announced that its wholly-owned subsidiary, Presbia Ireland, Ltd. recently completed the purchase of the assets of Switzerland-based Neoptics AG, including its intellectual property portfolio for an aggregate purchase price of $1.5 million.
Monday, August 22, 2016 12:23 AM
LAKE FOREST, Calif. & SAN DIEGO—ReVision Optics
(RVO) has secured a $10 million credit facility from Square 1 Bank
, a division of Pacific Western Bank. RVO announced receipt of U.S. Food and Drug Administration (FDA) approval for its Raindrop Near Vision Inlay for the surgical correction of presbyopia on June 29, 2016. Proceeds from the credit facility will be used for working capital purposes including commercial operations, the company said.
Monday, August 15, 2016 12:21 AM
LAKE FOREST, Calif.—ReVision Optics
, maker of the Raindrop Near Vision Inlay, has named Nick J. Manesis, PhD as vice president of R&D. Dr. Manesis brings to RVO nearly 30 years of materials research and development experience, including at the leading ophthalmic companies Allergan and CooperVision.
Wednesday, August 10, 2016 12:23 AM
DUBLIN, Ireland—Allergan plc
(NYSE: AGN) reported total net revenues of $3.7 billion for the second quarter ended June 30, 2016, a 2 percent increase versus the prior year quarter.
Friday, August 5, 2016 12:21 AM
MIAMI—Bascom Palmer Eye Institute
is launching the world’s first master’s degree in Vision Science and Investigative Ophthalmology (MVSIO). The new program offers comprehensive training in ophthalmic translational research, problem-based learning and management.
Friday, August 5, 2016 12:18 AM
CHESTNUT HILL, Mass.—Dr. Perry Rosenthal, a pioneering Boston ophthalmologist, has received the 2016 Max Schapero Memorial Lecture Award, the Boston EyePain Foundation
announced. The award will officially be presented to Dr. Rosenthal at the Section's Awards Program in Anaheim, California on Nov. 9, 2016.
Wednesday, August 3, 2016 12:24 AM
AUSTIN, Texas—Ian Lane, OD, of VisionWeb
will host a 4-part webinar series that will walk ECPs through various condition-based patient encounters common in most practices.
Wednesday, August 3, 2016 12:18 AM
FREMONT, Calif. and PADOVA, Italy—CenterVue
has received 510(k) clearance from the U.S. Food and Drug Administration
for fixation training for its MAIA platform, a technology designed to help patients rehabilitate from vision loss using audio feedback.
Friday, July 29, 2016 12:24 AM
JENA, Germany—James Mazzo will join Carl Zeiss Meditec
as global president of ophthalmology with responsibility for the company’s new strategic business unit ophthalmology as well as Carl Zeiss Meditec's U.S. sales and service center.
Friday, July 29, 2016 12:21 AM
, developer of the Kamra corneal inlay and IC-8 IOL, announced that Alan Waterhouse has been appointed president and chief operating officer (COO) and William Link, PhD, has joined the company as chairman of the board.
Monday, July 25, 2016 12:21 AM
SYLMAR, Calif.—Second Sight Medical Products
announced that a five-year study of patients who have the Argus II artificial retina implant has yielded positive results.
Monday, July 25, 2016 12:18 AM
LAVAL, Quebec—Valeant Pharmaceuticals International
(NYSE: VRX and TSX: VRX) announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for latanoprostene bunod ophthalmic solution, 0.024 percent, an intraocular pressure lowering single-agent eye drop for patients with open angle glaucoma or ocular hypertension.
Friday, July 1, 2016 12:24 AM
WASHINGTON, D.C.—The U.S. Food and Drug Administration has approved the Raindrop Near Vision Inlay, a device implanted in the cornea of one eye to improve near vision in certain patients with presbyopia.